Despite what we believe is aggressive discounting

Despite what we believe is aggressive discounting and downward adjusting of our models based on overly pessimistic probability assumptions, we are still arriving at a target price of $1.00 per share. The current market capitalization is only $2 million. Our target is far more consistent with that we see as a peer-valuation for similar-stage NASDAQ listed companies. We believe several pending catalysts over the next 15 months, including the AMDX sales /spin-off, starting human clinical trials with MANF, reporting results from the eltoprazine Phase IIb data, and the ESS Phase IIa data should allow for the realization of a significantly higher stock price.